Hooijman Marit F, Martinez-De la Torre Adrian, Weiler Stefan, Burden Andrea M
Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. David de Wiedbuilding, Universiteitsweg 99, 3584 CG Utrecht.
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Lancet Reg Health Eur. 2022 Jun 27;20:100437. doi: 10.1016/j.lanepe.2022.100437. eCollection 2022 Sep.
To examine time trends and characteristics of calls related to opioid poisonings reported to the National Poison Centre and opioid sales in Switzerland.
We used population-level data from the Swiss National Poisons Information Centre on reported opioid-related poisonings and data provided by the Swiss Pharmacists' Association (pharmaSuisse) based on IQVIA data to identify sold opioid packages. The rate of opioid-related poisoning calls and dispensed opioid packages per 100,000 Swiss inhabitants between 2000 and 2019 were plotted by year and annual trends were assessed. All analyses were stratified by individual opioid and potency (strong vs weak).
There was a significant 177% increase in the rate of calls for opioid-related poisonings (1·4 to 3·9 per 100,000 inhabitants, p<0·001) and a 91·3% increase in opioid sales (from 14,364·0 to 27,477·6 per 100,000 inhabitants, p<0.001). The increase associated with strong opioids was higher when compared to weak opioids, in both poison centre calls and sales. In 2019, tramadol was the most frequently reported opioid in the poison centre data (35·7%, n=133) and sales (37·5%, n=8,863,377), followed by oxycodone calls (24·4%, n=91) and sales 23·4%, n= 552,751). Poisoning calls and sales related to oxycodone increased substantially between 2009 and 2016, as did the rate of poison centre calls requiring medical care.
Calls to the Swiss National poison centre and sales for opioid have increased substantially in Switzerland in the last two-decades. Increases were primarily driven by oxycodone and tramadol; however, sales have attenuated since 2016. Our findings mirror other European countries and stress the importance of surveillance and monitoring.
The research did not receive external funding. Translation of the abstract in German, French and Italian are available in the Supplementary section.
研究向瑞士国家毒物中心报告的与阿片类药物中毒相关的电话呼叫的时间趋势和特征以及瑞士的阿片类药物销售情况。
我们使用了瑞士国家毒物信息中心关于报告的与阿片类药物相关中毒的人群水平数据，以及瑞士药剂师协会（瑞士制药行业协会）根据IQVIA数据提供的数据来识别已售出的阿片类药物包装。绘制了2000年至2019年间每10万瑞士居民中与阿片类药物相关中毒呼叫率和配发的阿片类药物包装数量，并评估年度趋势。所有分析均按个体阿片类药物和效力（强与弱）进行分层。
与阿片类药物相关中毒的呼叫率显著增加了177%（从每10万居民1.4例增至3.9例，p<0.001），阿片类药物销售额增加了91.3%（从每10万居民14364.0例增至27477.6例，p<0.001）。在毒物中心呼叫和销售方面，与强阿片类药物相关的增长高于弱阿片类药物。2019年，曲马多是毒物中心数据中报告最频繁的阿片类药物（35.7%，n = 133）和销售量（37.5%，n = 8863377），其次是羟考酮呼叫（24.4%，n = 91）和销售量（23.4%，n = 552751）。2009年至2016年间，与羟考酮相关的中毒呼叫和销售大幅增加，需要医疗护理的毒物中心呼叫率也如此。
在过去二十年中，瑞士国家毒物中心的呼叫以及阿片类药物的销售大幅增加。增长主要由羟考酮和曲马多推动；然而，自2016年以来销售量有所下降。我们的研究结果与其他欧洲国家相似，并强调了监测和监管的重要性。
该研究未获得外部资金。摘要的德语、法语和意大利语翻译可在补充部分获取。
